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The role of mesenchymal stem cells (MSCs) in cancer development is still controversial.
MSCs may promote tumor progression through immune modulation, but other tumor
suppressive effects of MSCs have also been described. The discrepancy between these
results may arise from issues related to different tissue sources, individual donor variability,
and injection timing of MSCs.The expression of critical receptors such asToll-like receptor
is variable at each time point of treatment, which may also determine the effects of
MSCs on tumor progression. However, factors released from malignant cells, as well
as surrounding tissues and the vasculature, are still regarded as a “black box.” Thus,
it is still difﬁcult to clarify the speciﬁc role of MSCs in cancer development. Whether
MSCs support or suppress tumor progression is currently unclear, but it is clear that
systemically administered MSCs can be recruited and migrate toward tumors. These
ﬁndings are important because they can be used as a basis for initiating studies to explore
the incorporation of engineered MSCs as novel anti-tumor carriers, for the development of
tumor-targeted therapies.
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INTRODUCTION
Mesenchymal stem cells (MSCs) belong to a category of clin-
ically relevant cell types that have the potential to be utilized
for cell-based therapies, because complicated culturing or han-
dling techniques are not required to yield clinically practical
quantities. Traditionally, MSCs can be induced to differenti-
ate into mesenchymal lineages such as osteoblasts, adipocytes,
chondrocytes and potentially other skeletal tissue cells by cultur-
ing MSCs under deﬁned mechanochemical conditions (Pittenger
et al., 1999). MSCs are characterized by the expression of cell sur-
face markers such as CD73, CD90, and CD105, and the absence of
expression of hematopoietic lineage markers (Lama et al., 2007).
Recently, there has been heightened interest into the homing and
migration capacity of MSCs into tumors. Since the process of
tumor progression is closely related to inﬂammation, the role of
MSCs in carcinogenesis has emerged as an attractive new concept
in cancer therapy. Although ample experimental evidence exists
in support of the therapeutic potential of MSCs targeting differ-
ent tumors, e.g., hepatocellular carcinoma (Gao et al., 2010), brain
tumors (Nakamizo et al., 2005) and sarcoma (Khakoo et al., 2006)
in different animal models, the mechanisms guiding the homing
and recruitment of MSCs into tumors and their potential role
in malignant tissue progression are not well understood. MSCs
have been shown to promote tumor progression through immune
modulation (Karnoub et al., 2007). In contrast, other studies have
reported that MSCs have a suppressive effect on tumor develop-
ment; e.g., via modiﬁcation of Akt signaling (Khakoo et al., 2006).
The use of different tissue sources, individual donor variability,
and injection timing of MSCs in each experiment may have an
impact on this discrepancy. The expression of critical receptors
such as Toll-like receptor (TLR) is variable at various time points
during the treatment (Liotta et al., 2008), which may also inﬂu-
ence the effects of MSCs on tumor progression. Whether MSCs
support or suppress tumor progression, it is clear that systemi-
cally administered MSCs can be recruited by, and migrate toward,
tumors (Studeny et al., 2002; Loebinger et al., 2009). These ﬁnd-
ings are important because they can be used as a basis for studies
to explore the utilization of engineered MSCs as novel carriers
for delivery of anti-tumor agents to cancerous tissue, guiding the
development of tumor targeted therapies.
Previous reports (Curtin et al., 2009; Tang et al., 2010) have
led to a great deal of attention into the role and function of
MSCs in tumors. The tropism of MSCs for tumors raised wide
interest regarding their potential as a delivery vehicle for anti-
cancer agents. Indeed, several reports have described the feasibility
of using these cells as anti-cancer delivery vehicles because they
secrete various anti-cancer molecules such as tissue necrosis fac-
tor (TNF), TNF related apoptosis inducing ligand (TRAIL), and
interferon (IFN)-β by transfection. These studies demonstrated
a sufﬁcient effect in suppressing tumor progression (Nakamizo
et al., 2005; Loebinger et al., 2009; Grisendi et al., 2010). However,
Karnoub et al. (2007) suggested thatMSCs have a supportive effect
on tumor progression showing that co-injection of MSCs with
cells from a breast cancer cell-line led to a higher degree of metas-
tasis, but this effect was not signiﬁcant in local tumor growth.
This supportive effect on tumor growth by MSCs has also been
reported in different cancers such as colon cancer, lymphoma,
and melanomas (Djouad et al., 2003; Ame-Thomas et al., 2007;
Shinagawa et al., 2010). In contrast, several reports showed that
MSCs may have a suppressive role in tumor development via p38
mitogen-activated protein kinase (MAPK; Tian et al., 2010) or by
cell fusion (Wang et al., 2012). Also, different types of tumors such
as liver cancer, breast cancer, leukemia, and pancreatic cancer have
been used to show a tumor suppressive effect of MSCs (Qiao et al.,
2008a,b; Cousin et al., 2009; Zhu et al., 2009). On the other hand,
Torsvik et al. (2010) suggested that cross-contamination of MSCs
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with tumor cells can enhance tumor supportive behavior. Interest-
ingly, Klopp et al. (2011) suggested that the increased tumor mass
observed in these reports can be related to increased proliferation
of MSCs in the tumor.
In this review, we discuss recent ﬁndings related to mecha-
nisms of MSC migration toward tumors, including cytokines,
chemokines, as well as surrounding conditions, and, more impor-
tantly, we will also discuss the potential role of MSCs in malignant
tissue progression.
THE MESENCHYMAL STEM CELL NICHE IN VIVO
It was previously revealed that the primary MSC niche is in bone
marrow; however, there are several reports that also identify
additional peripheral locations, such as adipose tissue, salivary
glands, tendon, periodontal ligament, skin, muscle, lung and,
most recently, Powell et al. (2011) reported that the intestinal
lamina propria is also a niche. A report by da Silva Meirelles
et al. (2008) posits that an important MSC niche is the perivas-
cular region, which, as a residual aspect of embryogenesis, might
explain the presence of MSCs in many different tissue types.
Stappenbeck and Miyoshi (2009) have suggested thatMSCsmight
originate in the bone-marrow and, subsequently, be recruited
distally to speciﬁc sites of tissue injury). Nonetheless, there
appear to be two origins of MSC populations. One population
present in peripheral locations where they interact with perivas-
cular cells (an embryonic remnant), and a second population
originating in the bone marrow, where MSCs form their pri-
mary stem cell niche and respond appropriately following tissue
injury. MSCs secrete various families of active molecules, includ-
ing cytokines, chemokines, and growth factors, which regulate the
local bone marrow environment and modulate systemic immune
responses to inﬂammatory events. Although there have been
numerous reports demonstrating that MSCs can repair tissue
by directly differentiating toward mesenchymal lineages, recent
work has established that instead of, or perhaps in addition to
differentiation, MSCs can enhance the differentiation of other
progenitor cells into functional somatic cells. In addition, they
may contribute to other aspects of local tissue repair via paracrine
mechanisms.
Mesenchymal stem cells can function as immune suppressive
and anti-inﬂammatory agents, as well as stimulators of tissue
repair and regeneration. However, the difference between MSCs
that are recruited from the bone marrow versus peripherally
located MSCs in executing these distinct roles is unclear. Recently,
Brandau et al. (2010) compared the differentiation potentials of
local resident and bone marrow-derived MSCs, and suggested
that the two populations were not identical. Indeed, da Silva
Meirelles et al. (2008) demonstrated differences in the degree of
differentiation among MSCs originating from different tissues.
The homing capacity toward cancer tissues has been evaluated
mostly in MSCs derived from bone marrow (Hung et al., 2005;
Nakamizo et al., 2005; Loebinger et al., 2009) and less from other
tissues such as adipocytes (Grisendi et al., 2010) or umbilical
cord blood (Hu et al., 2011). However, once incorporated into a
tumor,MSCsmight contribute with other cells such asmyoﬁbrob-
lasts, endothelial cells, pericytes, and inﬂammatory cells to create
a microenvironment that mirror the environment of a chronic
wound (Dvorak, 1986; Bergfeld and DeClerck, 2010). In this con-
text, local tissue derived MSCs, such as from pericytes, might
contribute to tumor progression.
THE IMPACT OF ROLE DISCREPANCY ON MESENCHYMAL
STEM CELLS IN CANCER DEVELOPMENT
Resident MSCs may have a critical role in maintaining the home-
ostasis of injured tissue through immune modulatory effects or
angiogenic stimulation by secreting bioactivemolecules (Lazennec
and Jorgensen, 2008; Uccelli et al., 2008). Since the actual popu-
lation of resident MSCs is thought to be very low and decreases
with age (Caplan, 2007), the behavior of large quantities of experi-
mentally administeredMSCs is likely to be quantitatively different
from the behavior of the small amount of resident MSCs. There-
fore, the role of administered MSCs in cancer development is still
controversial. There are various reports that describe the ability
of MSCs to promote tumor progression by enhancing metastatic
potential (Karnoub et al., 2007) as well as epithelial mesenchy-
mal transition (EMT; Kabashima-Niibe et al., 2013). In contrast,
Ho et al. (2013) reported tumor suppressive effects of MSCs via
modiﬁcation of Akt signaling, shown by the coadministration of
MSCs and glioma cells resulting in a signiﬁcant reduction in tumor
volume and vascular density. Also, several reports have demon-
strated a suppressive effect of MSCs on different types of tumors
(Otsu et al., 2009; Dasari et al., 2010). These conﬂicting results
may be due to variable experimental factors such as differences in
cell source like bone marrow or fat tissue, different time points,
method of cell administration, and timing. In addition, although
the composition of culture media is similar to ﬂuids present in
vivo, it does not supply all of the bioactive factors present in the
stem cell niche (Watt andHogan, 2000). Therefore, culturedMSCs
should not be considered equivalent to MSCs under physiologi-
cal conditions in vivo. Interestingly, resident MSCs, derived from
either bone marrow or local tissues, have been reported to partly
contribute to the origin of cancer-associated ﬁbroblast (CAFs)
or tumor-associated myoﬁbroblasts (Quante et al., 2011). Using
a mouse model of inﬁammation-induced gastric cancer, Quante
et al. (2011) showed that at least 20% of CAFs originate in bone
marrow and are derived fromMSCs. This study suggested that the
numberofMSCs could increase in response to cancer development
and promote the malignant potential.
Whether MSCs support or suppress tumor progression, it is
clear that systemically administered MSCs can be recruited and
migrate toward tumors (Koc et al., 2000; Nakamizo et al., 2005).
Although the effect on the tumor might be enhanced by timing or
the number of administered cells, these ﬁndings can be used for
the development of tumor targeted therapies by providing a basis
for conducting studies to explore the incorporation of engineered
MSCs as novel anti-tumor carriers (Reagan and Kaplan, 2011).
HOMING MECHANISM OF MSCs TOWARD CANCER
Recently, interest into our understanding of MSC homing and
migration into tumors has grown, and several investigators have
begun to compare these two processes. Since the process of tumor
progression is highly related to inﬂammation and, as reported
by Kalluri and Weinberg (2009) that EMT is critical in cancer
development, the role of MSCs in carcinogenesis is an attractive
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new concept in cancer therapy. In this section, we review recent
reports demonstrating the homing mechanisms of MSCs. Several
different mediators have been reported to be involved in this pro-
cess. Some of these molecules are growth factors, chemokines and
cytokines, which can regulate cell migration toward inﬂamma-
tory sites. These include SDF-1 and SCF-1, CCL5/CCR5, CCR2,
TNF-α, and other peptides.
GROWTH FACTORS
Vascular endothelial growth factor (VEGF) seems to be one of the
most important factors that enhances and directs stem cell motil-
ity. Indeed MSCs demonstrate intensive migratory and invasive
behavior in the presence of gliomas, which express high levels
of VEGF. It was reported by Ritter et al. (2008) that VEGF, as
well as bFGF secreted by breast cancer cells, induced the migra-
tion of MSCs. They also demonstrated that receptors for these
molecules were expressed on MSCs and that depletion of these
growth factors using antibodies reduced MSC migration capacity.
In addition,MSCs have been shown tomigrate toward endothelial
cell-derived capillaries and inhibit tumor angiogenesis (Otsu et al.,
2009). Although VEGF might contribute to this phenomenon,
MSCs have been shown to have opposing effects on tumors. MSCs
are known to express EGF and PDGF receptors on their surface,
and antibodies that block PDGF or EGF can attenuate the migra-
tion of MSCs. Those reports demonstrated that certainmalignant
tumors such as in glioma and breast cancer, which have highly
specialized vasculature and stroma, can provide permissive envi-
ronments for the selective engraftment of MSCs. Taken together,
the tropism of MSCs for tumors may be mediated, at least in
part, by speciﬁc growth factors and receptors expressed by MSCs,
thereby using a recruitment mechanism similar to what is used in
inﬂamed or injured tissue.
CHEMOKINES AND CYTOKINES
Stromal cell derived factor 1α (SDF-1α),which is awell-established
chemo-attractant for leukocytes, acts directly on cancer cells by
stimulating proliferation through the SDF-1α receptor chemokine
(C-X-C motif) receptor 4 (CXCR4) expressed on cancer cells.
However, SDF-1α secretion also leads to recruitment of endothe-
lial progenitor cells to the growing tumor, thereby promoting
angiogenesis. Some reports have demonstrated that SDF-1α
secreted from cancer cells enhanced MSC tropism, and an anti-
body that blocks SDF-1α attenuated the migration of MSCs.
Infection-related cancer development processes, such as heli-
cobacter infection in gastric cancer, can give rise to an environment
conducive to the recruitment ofMSCs, and this can be regulated by
SDF-1 and SCF-1. It was also reported that in response to chronic
helicobacter infection, bone marrow–derived cells could home to
and repopulate the gastric mucosa and contribute over time to
metaplasia, dysplasia, and cancer (Stoicov et al., 2013).
Chemokine (C-C motif) ligand 5 (CCL5) is one of the
chemokines that can enhance stem cell migration during inﬂam-
mation. It was reported by Karnoub et al. (2007) that actions of
CCL5 were responsible forMSC-inducedmetastasis in breast can-
cer cells. Breast cancer cells stimulated de novo secretion of the
chemokine CCL5 (also called RANTES) from MSC, which then
acted in a paracrine fashion on cancer cells to enhance their
motility, invasion and metastasis (Karnoub et al., 2007). This
result shows the critical importance of CCL5–CCR5 paracrine
interactions in enabling MSCs to induce cancer metastasis.
MSC RESPONSE TO IRRADIATION AND HYPOXIA
It was reported by Klopp et al. (2007) that the role of inﬂam-
mation-related cytokines and chemokines in radiation-enhanced
MSC migration is signiﬁcant. They identiﬁed cytokines and
chemokines involved in chemotaxis towards irradiated tumor
microenvironments. Low-dose irradiation of murine tumors
enhanced the tropism for, and engraftment of, MSCs in irra-
diated tumor environments. They demonstrated that tumor
cells were able to increase the production and secretion of
cytokines following irradiation, e.g., VEGF, PDGF, and TGF-β,
that enhanced the migratory properties of MSCs (Klopp et al.,
2007). In addition, the chemokine receptor CCR2 was found
to be up-regulated in MSCs exposed to irradiated tumor cells.
CCR2 was undetectable or expressed at low levels in untreated
cells but could be up-regulated by inﬂammatory cytokines such
as TNF-α. In addition, inhibition of CCR2 led to a marked
decrease of MSC migration in vitro (Ren et al., 2012). Taken
together, these experiments suggest that radiation can increase
the expression of inﬂammatory mediators that can secondarily
enhance the recruitment of MSCs into the tumor microenviron-
ment.
Hypoxia also plays a major role in tumor progression, metas-
tasis, and poor clinical outcomes. However, the role of hypoxia in
MSC recruitment to the tumor microenvironment has not been
sufﬁciently described. It was reported by Rattigan et al. (2010)
that hypoxic breast cancer cells enhance their production of IL-
6, which promotes the recruitment of MSCs. Secreted IL-6 acts
in a paracrine fashion on MSCs, stimulating the activation of
both Stat3 and MAPK signaling pathways to enhance migratory
potential and cell survival. Speciﬁcally, increased cellular migra-
tion is dependent on IL-6 signaling through the IL-6 receptor
(Rattigan et al., 2010). IL-6 is generally thought of as a multifunc-
tional cytokine that plays a role in apoptosis, cell proliferation
and survival. It binds to its cognate receptor, leading to activation
of the JAK/STAT signal transduction pathway. A similar pathway
may contribute to themigratory capacity of MSCs toward hypoxic
tumors.
OTHER EXOGENOUS MOLECULES
Previous studies have shown that leucine, leucine-37 ( LL-37),
the C-terminal peptide of human cationic antimicrobial protein
18, stimulates the migration of various cell types and has similar
expression patterns in tumors, damaged tissue, and in inﬂam-
matory tissue, where MSCs are prominent. These peptides also
have the ability to stimulate chemotaxis of various cell types. It
was reported by Coffelt et al. (2009) that LL-37 promotes ovar-
ian tumor progression through recruitment and engraftment of
MSCs into tumors, where these cells provide pro-angiogenic and
immunomodulatory factors to support tumor growth and pro-
gression. Indeed, neutralization of LL-37 in vivo signiﬁcantly
reduces the engraftment of MSCs into ovarian tumor xenografts,
resulting in inhibition of tumor growth, as well as disruption of
the ﬁbrovascular network. LL-37-mediated migration of MSCs
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into tumors likely occurs through formyl peptide receptor like-
1 (Coffelt et al., 2009). These data indicate that LL-37 facilitates
tumor progression through recruitment of progenitor cell popu-
lations to serve as pro-angiogenic factor-expressing tumor stromal
cells. Expressed factors include IL-1 receptor antagonist, IL-6, IL-
10, CCL5, VEGF, and matrix metalloproteinase-2 (MMP-2). The
overall consequence of LL-37’s actions, through its recruitment of
MSCs, is advancement of tumor progression.
Urokinase plasminogen activator (uPA) and urokinase plas-
minogen activator receptor (uPAR) are up-regulated in tumors of
various origins, where they play critical roles in the development
of invasive and chemo-resistant cancer phenotypes. The activa-
tion of uPA and uPAR in malignant solid tumors (brain, lung,
prostate, and breast) augments MSC tropism. It was reported by
Gutova et al. (2008) that chemo-attraction of MSCs to cancer cells
is strongly correlated with uPAR expression levels in tumor cells,
which may be important for the development of optimal stem
cell-based therapies.
DEVELOPMENT OF MSCs AS A STEM CELL THERAPY
Since it was reported by Tolar et al. (2007) that sarcoma developed
following transplantation of MSCs into animals, determination
of their therapeutic efﬁcacy and safety is now required for clini-
cal applications. From a practical perspective, MSCs seem to be
a very promising cell source for use in stem cell therapies for
tissue impairment, given that MSCs can home to inﬂamed or
injured tissues, as well as tumors, likely without differentiating
into somatic cells. It is important to identify the utility of MSCs in
clinical settings, in the context of an understanding of their com-
plicated mechanisms as immune and inﬂammatory regulators.
As discussed in this chapter, the most promising clinical aspects
of MSCs might be immune-modulatory and anti-inﬂammatory
effects. However, major challenges remain in our understanding
of both the actual beneﬁts, as well as the side effects of these cells
in human disease.
This reviewdiscussedkeymodulators regarding the importance
of the migration capacity of MSCs. Controlling the level of these
key factors in target tissues may be a way to increase the speci-
ﬁcity of MSC applications in these tissues, which may also lead to
a reduction in the total cell number needed for the therapy, and,
in concert, may reduce potential side effects, such as malignant
transformation. Receptors for the reviewed key factors expressed
onMSCs, including TLR andCXCR4, can also be potentiallymod-
iﬁed genetically via transfection, which may augment the efﬁcacy
of MSCs in clinical settings and decrease the migration of MSCs
to non-targeted sites.
However, the clinical application of MSCs for cancer treatment
is still challenging. This review described the migratory potential
of MSCs to malignant tissues, which is largely similar to MSC
migration into inﬂammatory tissue. However, factors released
frommalignant cells, as well as surrounding tissues and the vascu-
lature, are still regarded as a “black box.”Thus, remains difﬁcult to
provide a speciﬁc role for MSCs in cancer development after they
migrate and home into different tissues. Although some reports
have demonstrated a tumor suppressive effect of MSCs, others
described a tumor supportive potential. In any case, these reports
encourage the notion that MSCs may play a critical role in cancer
development and may be useful as a novel therapeutic delivery
system that can target malignant tumors, potentially superior to
existing therapeutic molecular therapies. While MSCs can react
to surrounding microenvironments, molecular therapies cannot.
Thus, it is imperative that scientists continue to investigate the roles
andmechanismsofMSCs in tumorprogression in order to harness
the therapeutic potential of MSCs to regulate both inﬂammatory
and metastatic diseases.
For clinical applications, the methodology of administration
of MSCs is crucial to determine their efﬁcacy, since there are sev-
eral reports describing the risk of capillary embolism by MSCs
after intravascular administration (Furlani et al., 2009; Tatsumi
et al., 2013). Additional strategies, such as co-administration of
anti-coagulant or adhesion factors (Tatsumi et al., 2013), as well
as engineering approaches (Karoubi et al., 2009; Houtgraaf et al.,
2013), might attenuate these risks.
CONCLUSION
In summary, there are a variety of studies that demonstrate
the potential migration of MSCs toward and into tumors in
response to multiple molecules secreted from tumors as well as
surrounding tissues. These ﬁndings will help to clarify the role
of MSCs in tumors, as well as the key mechanisms that deter-
mine whether MSCs are suppressive or supportive for tumor
growth. Since MSCs are relatively easy to obtain and grow in the
laboratory, we anticipate that this review may help to develop
new approaches in cell therapy using MSCs to control cancer
development.
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